AstraZeneca’s Lynparza shows benefits in ovarian cancer trial

AstraZeneca has announced phase III clinical trial data that demonstrates the benefits offered by its ovarian cancer therapy Lynparza.

Results from the SOLO-2 trial highlighted the efficacy of Lynparza as a monotherapy for the maintenance treatment of patients with platinum-sensitive relapsed, BRCA-mutated ovarian cancer.

A clinically meaningful and statistically significant improvement in progression-free survival rates was seen among Lynparza recipients compared to placebo, providing additional evidence to support the potential use of Lynparza in this patient population.

It was also noted that the Lynparza arm of SOLO-2 saw a substantially better survival rate than in the phase II maintenance study in patients with platinum-sensitive relapsed ovarian cancer.

Sean Bohen, executive vice-president for global medicines development and chief medical officer at AstraZeneca, said: "We remain committed to investigating the full potential of Lynparza, both as monotherapy and in combinations, and to identifying all patients who may benefit from this important medicine."

Full results of SOLO-2 will be presented at a forthcoming medical meeting and will be used to support regulatory applications for the treatment.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today